Asit biotech: Expertise in vaccines
In 2010, he was named Vaccine Biotech CEO of the Year at the World Vaccine Congress. Zettlmeissl currently serves as non-executive director of Aeras, (USA). Until early 2015, he was chairman of GlycoVaxyn (Switzerland), an innovative vaccine company acquired by GlaxoSmithKline.
Erstwhile Asit biotech Chairman Béatrice De Vos has stepped down “to focus on new projects”.
Gerd Zettlmeissl, says: “I am particularly enthusiastic about being able to continue contributing, as Chairman, to the development and future marketing of the next generation of immunotherapy products in order to meet the needs of patients who are seeking significantly less restrictive treatments. I would also like to thank all of the Board’s members, and the ASIT biotech teams, for the trust they have put in me. I firmly believe in the Company’s prospects, and pledge to make the most of my substantial experience in the global development of new therapeutic solutions.”
Thierry Legon, CEO of ASIT biotech, adds: “We would like to thank Béatrice De Vos for her remarkable contribution to ASIT biotech’s clinical progress since 2013, the year she was appointed Chairwoman. Her availability and her considerable expertise in terms of the clinical development of drug candidates have been valuable assets for the Company and the success of its IPO in May 2016. We respect her decision, and wish her every success and fulfillment in her future professional and personal projects. Gerd Zettlmeissl’s arrival as Chairman will ensure continuity in the excellence of our governance and the pertinence of ASIT biotech’s strategy, which I firmly believe will enable us to successfully meet the many challenges that await us in 2017 on which we are actively working.”